Table 2.

Comparison of treatment effects between different groups.

Outcome measure	Mean monthly rate of change			P-value
	Riluzole (n = 62)	Riluzole + mNGF Group 1 (n = 7)	Riluzole + mNGF Group 2 (n = 11)
BMI	−0.102 (−1.906 to −0.013)	−0.038 (−0.191 to 0.116)	–	0.579
ALSFRS–R	−1.117 (−1.952 to −0.283)	–	−1.059 (−2.141 to 0.024)	0.457
ALSFRS-R bulbar subscore	−0.164 (−0.295 to −0.034)	–	−0.157 (−0.329 to 0.015)	0.912
ALSFRS-R motor subscore	−0.849 (−1.629 to −0.069)	–	−0.636 (−1.331 to 0.059)	0.326
ALSFRS-R respiratory subscore	−0.104 (−0.282 to 0.074)	–	−0.266 (−0.668 to 0.137)	0.722

ALSFRS-R, ALS Functional Rating Scale-Revised; BMI, body mass index; mNGF, mouse nerve growth factor.